Cargando…

Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS is characterized by hyperandrogenism and ovulatory dysfunction. Women with PCOS have a high prevalence of obesity, insulin resistance (IR), increased blood pressure (BP), and activation of the reni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pruett, Jacob E., Torres Fernandez, Edgar D., Everman, Steven J., Vinson, Ruth M., Davenport, Kacey, Logan, Madelyn K., Ye, Stephanie A., Romero, Damian G., Yanes Cardozo, Licy L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962009/ https://www.ncbi.nlm.nih.gov/pubmed/33806551 http://dx.doi.org/10.3390/ijms22052576

Ejemplares similares

Androgen Receptor Blocker Improves the Cardiometabolic Profile in a Rat Model of Polycystic Ovary Syndrome, but at What Cost?
por: Pruett, Jacob E, et al.
Publicado: (2021)

Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors
por: Pruett, Jacob E., et al.
Publicado: (2023)

Long-Lasting Androgen-Induced Cardiometabolic Effects in Polycystic Ovary Syndrome
por: Torres Fernandez, Edgar D, et al.
Publicado: (2018)

SAT381 Effect of Obesity on Androgen-induced Splenic Dysregulation in Polycystic Ovary Syndrome
por: Rezq, Samar, et al.
Publicado: (2023)

Hepatic Dysregulation of Bile Acid Homeostasis in Hyperandrogenemic Female Mouse Model of Polycystic Ovary Syndrome
por: Huffman, Alexandra M, et al.
Publicado: (2021)

Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: effect of SGLT2 inhibition
por: Pruett, Jacob E., et al.
Publicado: (2022)

OR15-3 Contribution of Hyperandrogenemia to Dysbiosis, Gut Inflammation, and Dysregulation of Short-Chain Fatty Acid Homeostasis in Mouse Model of Polycystic Ovary Syndrome
por: Alsemeh, Amira, et al.
Publicado: (2022)

Cardiac and Renal SARS-CoV-2 Viral Entry Protein Regulation by Androgens and Diet: Implications for Polycystic Ovary Syndrome and COVID-19
por: Rezq, Samar, et al.
Publicado: (2021)

RF10 | PMON249 MicroRNA-21 Ablation Exacerbates Androgen-Mediated White Adipose Tissue Dysfunction and Impaired Insulin Signaling in a Mouse Model of Polycystic Ovary Syndrome
por: Rezq, Samar, et al.
Publicado: (2022)

OR35-02 Novel Androgen Receptor PROTAC Degrader ARV-110 Ameliorates Androgen Mediated Renal Injury in a Mouse Model of Polycystic Ovary Syndrome
por: Basnet, Jelina, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
por: Pruett, Jacob E, et al.
Publicado: (2022)

MicroRNA-21 Modulates White Adipose Tissue Browning and Altered Thermogenesis in a Mouse Model of Polycystic Ovary Syndrome
por: Rezq, Samar, et al.
Publicado: (2021)

Clinical Practice Guideline for Management of Primary Aldosteronism: What is New in the 2016 Update?
por: Romero, Damian G, et al.
Publicado: (2016)

Novel biomarkers of childhood and adolescent obesity
por: Yanes Cardozo, Licy L., et al.
Publicado: (2021)

Cardiometabolic risk in polycystic ovary syndrome
por: Bajuk Studen, Katica, et al.
Publicado: (2018)

SARS-CoV-2 Viral Entry Proteins in Hyperandrogenemic Female Mice: Implications for Women with PCOS and COVID-19
por: Huffman, Alexandra M., et al.
Publicado: (2021)

Cardiovascular and Metabolic Consequences of Testosterone Supplements in Young and Old Male Spontaneously Hypertensive Rats: Implications for Testosterone Supplements in Men
por: Dalmasso, Carolina, et al.
Publicado: (2017)

SAT-361 Familial Hypocalciuric Hypercalcemia Type 3: AP2S1 Mutation
por: Kerut, Sarah Elizabeth, et al.
Publicado: (2020)

SAT390 Western Diet Exacerbates Colonic Mitochondrial Dysfunction in the Hyperandrogenemic Female Rat Model of Polycystic Ovary Syndrome
por: Edwards, Kristin, et al.
Publicado: (2023)

The Potential of SGLT-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: The Current Status and Future Perspectives
por: Rakic, Dejana, et al.
Publicado: (2023)

The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome
por: Krysiak, Robert, et al.
Publicado: (2020)

Metabolic abnormalities in adolescents with polycystic ovary syndrome in south china
por: Huang, Jia, et al.
Publicado: (2010)

Abnormal Endometrial Receptivity and Oxidative Stress in Polycystic Ovary Syndrome
por: Shan, Hongying, et al.
Publicado: (2022)

Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women
por: Baldani, Dinka Pavicic, et al.
Publicado: (2015)

Correction to: The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome
por: Krysiak, Robert, et al.
Publicado: (2021)

Change in Androgenic Status and Cardiometabolic Profile of Middle-Aged Women with Polycystic Ovary Syndrome
por: van der Ham, Kim, et al.
Publicado: (2023)

OR35-01 Colonic Mitochondrial Dysfunction and Sub-acute Gastrointestinal Inflammation in Two Hyperandrogenemic Rodent Models of PCOS
por: Hoang, Ngoc, et al.
Publicado: (2023)

The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients
por: Chang, Chia Lin, et al.
Publicado: (2019)

Research Progress on the Mechanism Between Polycystic Ovary Syndrome and Abnormal Endometrium
por: Xue, Zhu, et al.
Publicado: (2021)

Abnormal Activation of Tryptophan-Kynurenine Pathway in Women With Polycystic Ovary Syndrome
por: Wang, Siyu, et al.
Publicado: (2022)

Visceral Adiposity Index: Simple Tool for Assessing Cardiometabolic Risk in Women with Polycystic Ovary Syndrome
por: Agrawal, Hiya, et al.
Publicado: (2019)

ApoB48-Lipoproteins Are Associated with Cardiometabolic Risk in Adolescents with and without Polycystic Ovary Syndrome
por: Vine, Donna F, et al.
Publicado: (2020)

The Role of Different Methods in Defining Cardiometabolic Risk and Metabolic Syndrome in Women with Polycystic Ovary Syndrome
por: Çakır Biçer, Nihan, et al.
Publicado: (2023)

Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor
por: Marinkovic-Radosevic, Jelena, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome: A Race Against the Clock
por: Huffman, Alexandra M, et al.
Publicado: (2022)

The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study
por: de Medeiros, Sebastiao Freitas, et al.
Publicado: (2018)

Does endothelial dysfunction correlate with endocrinal abnormalities in patients with polycystic ovary syndrome?
por: Dube, Rajani
Publicado: (2016)

Does polycystic ovary syndrome affect morphokinetics or abnormalities in early embryonic development?()
por: Tam Le, Minh, et al.
Publicado: (2019)

Adrenal Androgen Predictive Effects on Clinical and Metabolic Abnormalities of Polycystic Ovary Syndrome
por: Medeiros, Sebastião Freitas de, et al.
Publicado: (2022)

Polycystic Ovary Syndrome
por: Franks, Stephen
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_9v8cpgpj1nc5acfermehifo35q